Bertrand Allard

4.8k total citations · 2 hit papers
43 papers, 3.7k citations indexed

About

Bertrand Allard is a scholar working on Physiology, Oncology and Immunology. According to data from OpenAlex, Bertrand Allard has authored 43 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Physiology, 24 papers in Oncology and 14 papers in Immunology. Recurrent topics in Bertrand Allard's work include Adenosine and Purinergic Signaling (28 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Peptidase Inhibition and Analysis (12 papers). Bertrand Allard is often cited by papers focused on Adenosine and Purinergic Signaling (28 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Peptidase Inhibition and Analysis (12 papers). Bertrand Allard collaborates with scholars based in Canada, Belgium and France. Bertrand Allard's co-authors include John Stagg, David Allard, Simon C. Robson, Maria Serena Longhi, Sandra Pommey, Mark J. Smyth, Laurence Buisseret, Phillip K. Darcy, Paul A. Beavis and Martin Turcotte and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Cancer Research.

In The Last Decade

Bertrand Allard

43 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

2017 686 citations Bertrand Allard, Simon C. Robson et al. profile →
The adenosine pathway in immuno-oncology

2020 370 citations Bertrand Allard, David Allard et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bertrand Allard Canada	24	1.8k	1.8k	1.7k	1.0k	343	43	3.7k
Sergey V. Novitskiy United States	29	732 0.4×	1.6k 0.9×	1.6k 1.0×	1.6k 1.6×	665 1.9×	51	4.0k
Michael K.K. Wong United States	15	524 0.3×	567 0.3×	553 0.3×	931 0.9×	391 1.1×	25	2.1k
Mikhail M. Dikov United States	20	485 0.3×	604 0.3×	683 0.4×	868 0.9×	240 0.7×	31	1.9k
Liang Mao China	29	105 0.1×	1.2k 0.7×	1.1k 0.7×	861 0.8×	372 1.1×	63	2.7k
Ashley V. Menk United States	24	90 0.0×	1.9k 1.1×	2.8k 1.7×	1.5k 1.5×	1.3k 3.7×	34	4.6k
A Hönig Germany	27	164 0.1×	660 0.4×	728 0.4×	1.3k 1.2×	534 1.6×	76	2.6k
Atsushi Kasamatsu Japan	34	198 0.1×	948 0.5×	438 0.3×	1.9k 1.9×	821 2.4×	133	3.0k
Serena Desideri United States	21	88 0.0×	688 0.4×	375 0.2×	922 0.9×	501 1.5×	69	2.7k
Rahul Roychoudhuri United Kingdom	25	63 0.0×	1.6k 0.9×	2.3k 1.4×	1.4k 1.4×	699 2.0×	46	4.2k

Countries citing papers authored by Bertrand Allard

Since Specialization

Citations

This map shows the geographic impact of Bertrand Allard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Allard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Allard more than expected).

Fields of papers citing papers by Bertrand Allard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertrand Allard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Allard. The network helps show where Bertrand Allard may publish in the future.

Co-authorship network of co-authors of Bertrand Allard

This figure shows the co-authorship network connecting the top 25 collaborators of Bertrand Allard. A scholar is included among the top collaborators of Bertrand Allard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertrand Allard. Bertrand Allard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allard, Bertrand, Célia Jacoberger-Foissac, Isabelle Cousineau, et al.. (2023). Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma. Cell Reports Medicine. 4(9). 101188–101188. 19 indexed citations

Jacoberger-Foissac, Célia, Bertrand Allard, David Allard, & John Stagg. (2023). Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models. Methods in molecular biology. 2614. 151–169. 2 indexed citations

Jacoberger-Foissac, Célia, Isabelle Cousineau, Yacine Barèche, et al.. (2022). CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer. Cancer Immunology Research. 11(1). 56–71. 46 indexed citations

Kilgour, Marisa K., Sarah MacPherson, Lauren G. Zacharias, et al.. (2021). 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. Science Advances. 7(4). 51 indexed citations

Allard, Bertrand, David Allard, Laurence Buisseret, & John Stagg. (2020). The adenosine pathway in immuno-oncology. Nature Reviews Clinical Oncology. 17(10). 611–629. 370 indexed citations breakdown →

Allard, Bertrand, Isabelle Cousineau, Kathleen Spring, & John Stagg. (2019). Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. Methods in enzymology on CD-ROM/Methods in enzymology. 629. 269–289. 12 indexed citations

Allard, David, et al.. (2019). Targeting the adenosine pathway for cancer immunotherapy. Seminars in Immunology. 42. 101304–101304. 63 indexed citations

Allard, David, Pavel Chrobák, Bertrand Allard, Nouredin Messaoudi, & John Stagg. (2018). Targeting the CD73-adenosine axis in immuno-oncology. Immunology Letters. 205. 31–39. 114 indexed citations

Mediavilla-Varela, Melanie, Alberto Chiappori, David Noyes, et al.. (2017). A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia. 19(7). 530–536. 72 indexed citations

10.

Charlebois, Roxanne, Bertrand Allard, David Allard, et al.. (2016). PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. Cancer Research. 77(2). 312–319. 26 indexed citations

11.

Allard, Bertrand, Paul A. Beavis, Phillip K. Darcy, & John Stagg. (2016). Immunosuppressive activities of adenosine in cancer. Current Opinion in Pharmacology. 29. 7–16. 224 indexed citations

12.

Gaudreau, Pierre-Olivier, Bertrand Allard, Martin Turcotte, & John Stagg. (2016). CD73-adenosine reduces immune responses and survival in ovarian cancer patients. OncoImmunology. 5(5). e1127496–e1127496. 36 indexed citations

13.

Beavis, Paul A., Nicole Milenkovski, Melissa A. Henderson, et al.. (2015). Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research. 3(5). 506–517. 270 indexed citations

14.

Charlebois, Roxanne, Guillaume Chouinard, Bertrand Allard, et al.. (2015). CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. Clinical Cancer Research. 22(1). 158–166. 162 indexed citations

15.

Allard, Bertrand, Martin Turcotte, & John Stagg. (2014). Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opinion on Therapeutic Targets. 18(8). 863–881. 35 indexed citations

16.

Young, Arabella, Deepak Mittal, Kimberley Stannard, et al.. (2014). Co-blockade of immune checkpoints and adenosine A_2Areceptor suppresses metastasis. OncoImmunology. 3(10). e958952–e958952. 21 indexed citations

17.

Allard, Bertrand, Sandra Pommey, Mark J. Smyth, & John Stagg. (2013). Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Research. 19(20). 5626–5635. 372 indexed citations

18.

Allard, Bertrand, Anne Wijkhuisen, Frédérique Deshayes, et al.. (2013). Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor. mAbs. 5(1). 56–69. 20 indexed citations

19.

Allard, Bertrand, Frédérique Deshayes, Frédéric Ducancel, et al.. (2011). Electroporation-Aided DNA Immunization Generates Polyclonal Antibodies Against the Native Conformation of Human Endothelin B Receptor. DNA and Cell Biology. 30(9). 727–737. 13 indexed citations

20.

Wijkhuisen, Anne, et al.. (2009). Electrotransfer of cDNA Coding for a Heterologous Prion Protein Generates Autoantibodies Against Native Murine Prion Protein in Wild-Type Mice. DNA and Cell Biology. 29(3). 121–131. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact